Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | USP5 | P45974 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7864069 | 0.94 | SMN1; SMN2 (0.72) | RAB9ANPC1NR4A2KMT2ASMN1; SMN2 | |
| SCHEMBL26584242 | 0.91 | NPC1 (0.82) | RAB9ANPC1KMT2ASMN1; SMN2HTR7 | |
| SCHEMBL10353454 | 0.89 | NR4A2 (0.81) | RAB9ANPC1NR4A2KMT2ASMN1; SMN2 | |
| SCHEMBL296337 | 0.88 | NPC1 (0.84) | RAB9ANPC1NR4A2KMT2ASMN1; SMN2 | |
| SCHEMBL3866967 | 0.88 | NPC1 (0.77) | RAB9ANPC1NR4A2KMT2ASMN1; SMN2 | |
| SCHEMBL4485908 | 0.87 | RAB9A (0.69) | RAB9ANPC1NR4A2KMT2ASMN1; SMN2 | |
| SCHEMBL6932000 | 0.86 | TP53 (0.60) | RAB9ANPC1NR4A2KMT2ASMN1; SMN2 | |
| SCHEMBL9953589 | 0.86 | NPC1 (0.74) | RAB9ANPC1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL6925985 | 0.85 | MITF (0.66) | RAB9ANPC1KMT2ALMNAPTPN1 | |
| SCHEMBL28225958 | 0.85 | RAB9A (0.51) | RAB9ANPC1NR4A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-113214195-B | Method for asymmetrically synthesizing dihydrofuran 2- (3H) -ketone compound by nickel catalysis | 云南民族大学 | 2024-05-10 | — | — | CN | claimed |
| US-11884628-B2 | Method for synthesizing lactam derivatives without use of catalyst | GUIZHOU UNIVERSITY (CN) | 2024-01-30 | — | — | US | claimed |
| US-20220177429-A1 | METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST | GUIZHOU UNIVERSITY (CN) | 2022-06-09 | — | — | US | claimed |
| CN-113214195-A | Method for asymmetrically synthesizing dihydrofuran 2- (3H) -ketone compound by nickel catalysis | 云南民族大学 | 2021-08-06 | — | — | CN | claimed |
| WO-2020228170-A1 | CATALYST-FREE SYNTHESIS METHOD FOR LACTAM DERIVATIVE | 贵州大学 | 2020-11-19 | — | — | WO | claimed |
| CN-109942473-B | Method for synthesizing lactam derivative without catalyst | 贵州大学 | 2020-09-15 | — | — | CN | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-07-10 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | RAB9A 2114/4885NPC1 3543/4885NR4A2 3703/4885 |
| US-11884628-B2 | Method for synthesizing lactam derivatives without use of catalyst | COASY, SI, NAAA | RAB9A 1712/4885NPC1 4156/4885NR4A2 4625/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | RAB9A 711/4885NPC1 3732/4885NR4A2 801/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | RAB9A 789/4885NPC1 3601/4885NR4A2 2413/4885 |
| US-20220177429-A1 | METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST | COASY, SI, NAAA | RAB9A 1712/4885NPC1 4156/4885NR4A2 4625/4885 |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | AKR1C3, AKR1C1, AKR1A1 | RAB9A 1402/4885NPC1 21/4885NR4A2 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.